$CPMV
Mosaic ImmunoEngineering Inc. Stock $cpmv

$cpmv Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000168316824002402 Filed on April 15, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$225.6K
YoY Change		-22.34%
% of Gross Profit
Research & Development	$60.71K	$49.99K	$435.4K
YoY Change	-50.5%	-75.85%	-58.47%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$274.3K	$275.6K	$1.400M
YoY Change	-22.19%	-44.6%	-46.73%
Operating Profit	-$274.3K		-$1.400M
YoY Change	-22.19%		-46.73%
Interest Expense		-$19.94K
YoY Change		-45.44%
% of Operating Profit
Other Income/Expense, Net	-$19.42K	$0.00	$393.9K
YoY Change	-105.45%		58.17%
Pretax Income	-$293.7K	-$295.6K	-$1.006M
YoY Change	-1597.79%	-44.66%	-57.71%
Income Tax	$0.00	$0.00	$2.400K
% Of Pretax Income
Net Earnings	-$293.7K	-$295.6K	-$1.008M
YoY Change	-1597.79%	-44.66%	-57.65%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.04		-$0.14
Diluted Earnings Per Share	-$0.04	-$0.04	-$0.14
COMMON SHARES
Basic Shares Outstanding	7.242M shares	7.242M shares	7.236M shares
Diluted Shares Outstanding	7.236M shares		7.236M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$156.2K	$156.2K
YoY Change		-29.22%	-29.22%
Cash & Equivalents	$3.734K	$156.2K	$156.2K
Short-Term Investments
Other Short-Term Assets		$23.36K	$23.36K
YoY Change		-42.51%	-42.51%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$12.28K	$179.5K	$179.5K
YoY Change	-96.68%	-31.29%	-31.29%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$12.28K	$179.5K	$179.5K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$12.28K	$179.5K	$179.5K
YoY Change	-96.68%	-31.29%	-31.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$125.0K	$118.5K	$118.5K
YoY Change	-4.6%	-11.23%	-11.22%
Accrued Expenses	$623.6K	$641.8K	$4.437M
YoY Change	5.94%	9.74%	24.63%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.105M	$4.733M	$4.733M
YoY Change	17.45%	20.81%	20.81%
LONG-TERM LIABILITIES
Long-Term Debt		$1.318M	$1.318M
YoY Change		7.26%	7.26%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$1.318M	$1.318M
YoY Change		7.26%	7.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.105M	$4.733M	$4.733M
Total Long-Term Liabilities		$1.318M	$1.318M
Total Liabilities	$6.461M	$6.051M	$6.051M
YoY Change	14.9%	17.58%	17.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.499M	-$7.916M
YoY Change	16.62%	14.59%
Common Stock	$72.00	$72.00
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.448M	-$5.871M	-$5.871M
YoY Change
Total Liabilities & Shareholders Equity	$12.28K	$179.5K	$179.5K
YoY Change	-96.68%	-31.29%	-31.29%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$293.7K	-$295.6K	-$1.008M
YoY Change	-1597.79%	-44.66%	-57.65%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$96.72K	-$497.5K
YoY Change		-40.84%	-27.92%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$433.0K
YoY Change			26.24%
Cash From Investing Activities		$0.00	$433.0K
YoY Change			26.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	$0.00
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities		-96.72K	-$497.5K
Cash From Investing Activities		0.000	$433.0K
Cash From Financing Activities		0.000	$0.00
Net Change In Cash		-96.72K	-$64.47K
YoY Change		-40.84%	1072.77%
FREE CASH FLOW
Cash From Operating Activities		-$96.72K	-$497.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000836564
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	0-22182
CY2023	dei	Entity Registrant Name EntityRegistrantName	MOSAIC IMMUNOENGINEERING, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-1070278
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	9114 Adams Avenue, #202
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Huntington Beach
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92646
CY2023	dei	City Area Code CityAreaCode	657
CY2023	dei	Local Phone Number LocalPhoneNumber	208-0890
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	816893	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7242137	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	170
CY2023	dei	Auditor Name AuditorName	KMJ Corbin & Company LLP
CY2023	dei	Auditor Location AuditorLocation	Irvine, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156178	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	220645	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	23355	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	40632	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	179533	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	261277	usd
CY2023Q4	us-gaap	Assets Assets	179533	usd
CY2022Q4	us-gaap	Assets Assets	261277	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	118478	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	133464	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	46700	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3184911	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2399132	usd
CY2023Q4	cpmv	Accrued Consulting AccruedConsulting	787903	usd
CY2022Q4	cpmv	Accrued Consulting AccruedConsulting	753570	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	641763	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	584808	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4733055	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3917674	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1317536	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	1228361	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6050591	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5146035	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7242137	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7242137	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7242137	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7242137	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	72	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	72	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2045206	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2023271	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7916337	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6908102	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5871058	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4884758	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	179533	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	261277	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	435449	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1048457	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	964319	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1579065	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1399768	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2627522	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1399768	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2627522	usd
CY2023	cpmv	Gain On Redemption Of Preferred Stock Of Holocom GainOnRedemptionOfPreferredStockOfHolocom	433000	usd
CY2022	cpmv	Gain On Redemption Of Preferred Stock Of Holocom GainOnRedemptionOfPreferredStockOfHolocom	343000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	46700	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	57600	usd
CY2023	us-gaap	Noninterest Expense NoninterestExpense	73333	usd
CY2022	us-gaap	Noninterest Expense NoninterestExpense	69738	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1005835	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2378470	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1008235	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2380870	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7236447	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7236447	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7235609	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7235609	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4884758	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21935	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1008235	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5871058	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2799011	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	295123	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2380870	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4884758	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1008235	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2380870	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21935	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	295123	usd
CY2023	cpmv	Gain On Redemption Of Preferred Stock Of Holocom GainOnRedemptionOfPreferredStockOfHolocom	433000	usd
CY2022	cpmv	Gain On Redemption Of Preferred Stock Of Holocom GainOnRedemptionOfPreferredStockOfHolocom	343000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	46700	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	57600	usd
CY2023	us-gaap	Noninterest Expense NoninterestExpense	73333	usd
CY2022	us-gaap	Noninterest Expense NoninterestExpense	69738	usd
CY2023	us-gaap	Accretion Expense AccretionExpense	15842	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	81843	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-17277	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2720	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-14986	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	19951	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	785779	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1007835	usd
CY2023	cpmv	Increase Decrease In Accrued Consulting IncreaseDecreaseInAccruedConsulting	34333	usd
CY2022	cpmv	Increase Decrease In Accrued Consulting IncreaseDecreaseInAccruedConsulting	279295	usd
CY2023	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	56955	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	334836	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-497467	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-690129	usd
CY2023	cpmv	Proceeds From Redemption Of Preferred Stock Of Holocom ProceedsFromRedemptionOfPreferredStockOfHolocom	433000	usd
CY2022	cpmv	Proceeds From Redemption Of Preferred Stock Of Holocom ProceedsFromRedemptionOfPreferredStockOfHolocom	343000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	433000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	343000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	341632	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	341632	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-64467	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5497	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220645	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	226142	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	156178	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220645	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2400	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2400	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_805_eus-gaap--NatureOfOperations_zVqsT1NZlGMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. <span id="xdx_822_zeVkpZ8Bu6af">Organization and Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mosaic ImmunoEngineering, Inc. (the “Company,” “Mosaic,” “we,” “us,” or “our”), formerly known as Patriot Scientific Corporation, is a corporation organized under Delaware law on March 24, 1992. We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. We have historically advanced an early-stage product candidate, MIE-101, that is based on a naturally occurring plant virus licensed from Case Western Reserve University (“CWRU”) (see Note 12). In addition, we are pursuing new product candidates and platforms to expand our pipeline based on a deep understanding of immunotherapies and our license agreements with University of California San Diego.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has two inactive wholly owned subsidiaries: Mosaic ImmunoEngineering Development Company, a corporation organized under Delaware law on March 30, 2020 and Patriot Data Solutions Group, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Management’s Plans</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. At December 31, 2023, the Company had cash and cash equivalents of $<span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20231231_zW8hycmXrTHf" title="Cash and cash equivalents">156,178</span> and has not yet generated any revenue. Therefore, our ability to continue our operations is highly dependent on our ability to raise capital to fund future operations. We anticipate, based on currently proposed plans and assumptions that our cash and cash equivalents on hand will not satisfy our operational and capital requirements through twelve months from the filing date of this Annual Report on Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are a number of uncertainties associated with our ability to raise additional capital and we have no current arrangements with respect to any additional financing. In addition, the continuation of disruptions caused by COVID-19 or other variants or pandemics, broad-based inflation, and various economic indicators that the United States economy may be entering a recession in upcoming quarters may cause investors to slow down or delay their decision to deploy capital which will adversely impact our ability to fund future operations. Consequently, there can be no assurance that any additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital will delay our ability to conduct our business operations. Any additional equity financing may involve substantial dilution to our then existing stockholders. The above matters raise substantial doubt regarding our ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156178	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zI8EpZervtT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zJY0xxHqBAmb">Financial Instruments and Concentrations of Credit Risk</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We invest our cash and cash equivalents primarily in money market funds. Cash and cash equivalents are maintained with high quality financial institutions, which are regularly monitored by management. At times, deposits held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation. We perform ongoing evaluations of these financial institutions to limit our concentration of risk exposure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zDUFPwTaSEs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_z1wT12STQ9kk">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates in these consolidated financial statements include those related to the fair value of the anti-dilution issuance rights liability (derivative liability), the timing of conversion of the convertible notes, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to the inherent uncertainty involved in making such accounting estimates and assumptions, the actual financial statement results could differ materially from such accounting estimates and assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2399251	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2235962	shares
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	156178	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	220645	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	46700	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	46700	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	641763	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	584808	usd
CY2023Q4	cpmv	Convertible Notes Redemption Value ConvertibleNotesRedemptionValue	1145790	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	21935	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	295123	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2400	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2400	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2400	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2400	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2400	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0019	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0008	pure
CY2023	cpmv	Fair Market Value Of Derivative Liability FairMarketValueOfDerivativeLiability	0.0098	pure
CY2022	cpmv	Fair Market Value Of Derivative Liability FairMarketValueOfDerivativeLiability	0.0051	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0033	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0072	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2176	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2081	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0030	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0010	pure
CY2023Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	504	usd
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	504	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1313837	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	953175	usd
CY2023Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	6701	usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	6701	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	484819	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	478274	usd
CY2023Q4	us-gaap	Deferred Income Taxes And Other Tax Receivable Current DeferredIncomeTaxesAndOtherTaxReceivableCurrent	215261	usd
CY2022Q4	us-gaap	Deferred Income Taxes And Other Tax Receivable Current DeferredIncomeTaxesAndOtherTaxReceivableCurrent	215261	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	103604	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	83744	usd
CY2023Q4	cpmv	Deferred Tax Assets Limited Net Operating Loss Carryforwards DeferredTaxAssetsLimitedNetOperatingLossCarryforwards	597262	usd
CY2022Q4	cpmv	Deferred Tax Assets Limited Net Operating Loss Carryforwards DeferredTaxAssetsLimitedNetOperatingLossCarryforwards	597262	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	442275	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	504945	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3150861	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2826464	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	usd

Files In Submission

Name	View Source	Status
0001683168-24-002402-index-headers.html	Edgar Link	pending
0001683168-24-002402-index.html	Edgar Link	pending
0001683168-24-002402.txt	Edgar Link	pending
0001683168-24-002402-xbrl.zip	Edgar Link	pending
cpmv-20231231.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mosaic_ex2101.htm	Edgar Link	pending
mosaic_ex2301.htm	Edgar Link	pending
mosaic_ex3101.htm	Edgar Link	pending
mosaic_ex3102.htm	Edgar Link	pending
mosaic_ex3201.htm	Edgar Link	pending
mosaic_ex3202.htm	Edgar Link	pending
mosaic_i10k-123123.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
cpmv-20231231_cal.xml	Edgar Link	unprocessable
cpmv-20231231_lab.xml	Edgar Link	unprocessable
cpmv-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
mosaic_i10k-123123_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cpmv-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CPMV
Mosaic ImmunoEngineering Inc. Stock $cpmv

2024 Q2 Form 10-K Financial Statement

#000168316824002402 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPMV Mosaic ImmunoEngineering Inc. Stock $cpmv

2024 Q2 Form 10-K Financial Statement

#000168316824002402 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPMV
Mosaic ImmunoEngineering Inc. Stock $cpmv